Tempus is eligible for milestone payments and royalties for any oncology therapeutics Genmab might develop based on their joint research projects.
The German company's new Genome Enhancer product is an adaptation of its flagship multi-omics software for clinicians and biologists without bioinformatics expertise.
The companies will use Freenome's platform to identify cancer patients who are most likely to respond to treatment with ADC's loncastuximab tesirine.
Bioinformaticians at the Free University of Brussels have built a database, machine learning technology, and web platform for identifying elusive pathogenic gene pairs.
In a Phase II trial, Sophia will look for genomic markers of clinical response to ADC's treatment for relapsed or refractory diffuse large B-cell lymphoma.
University of Crete spinout Gnosis Data Analysis is adding AI capabilities to Indivumed's IndivuType multi-omics cancer research platform.
With $50 million from Japanese firm NEC, biomedical software startup BostonGene seeks to assess patients' "immune fitness" in the quest for better therapies.
The companies are using Strata's biomarker technology to identify genomic subpopulations of cancer patients who respond to Arcus' investigational immunotherapy drug.
Somalogic will use its SomaScan platform to analyze at least 15,000 clinical samples from Janssen to identify protein biomarkers for various diseases.
A pair of new fecal metagenomics studies pointed to gut microbial community shifts, related functional changes, and specific signatures for colorectal cancer.
A new study catalogues the genome and evolutionary history of the oak family, UPI reports.
Dog DNA testing is a growing market, but there's still a lot of uncertainty about the accuracy of the results, the Boston Globe says.
A University of South Florida researcher is testing bone fragments to determine if they belong to Amelia Earhart.
In Cell this week: antisense Piwi-interacting RNA responses to endogenous retroviruses, proteomic patterns in hepatocellular carcinoma, and more.